Contrarius Group Holdings LTD Intellia Therapeutics, Inc. Transaction History
Contrarius Group Holdings LTD
- $1.77 Trillion
- Q2 2025
A detailed history of Contrarius Group Holdings LTD transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Contrarius Group Holdings LTD holds 1,552,508 shares of NTLA stock, worth $16.9 Million. This represents 0.82% of its overall portfolio holdings.
Number of Shares
1,552,508
Previous 2,021,040
23.18%
Holding current value
$16.9 Million
Previous $14.4 Billion
1.34%
% of portfolio
0.82%
Previous 0.98%
Shares
3 transactions
Others Institutions Holding NTLA
# of Institutions
343Shares Held
98.1MCall Options Held
784KPut Options Held
713K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl13MShares$141 Million1.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$118 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$104 Million0.0% of portfolio
-
State Street Corp Boston, MA4.51MShares$49 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.8MShares$41.3 Million0.0% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $825M
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...